Company intelligence / Profile preview

Pagoda Resources

Bala Cynwyd, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Pagoda Resources is a private investment and strategic advisory firm specialized in the biopharmaceutical sector, primarily known for providing financing and strategic support to Citius Pharmaceuticals. Its associated portfolio reached a major milestone with the FDA approval of LYMPHIR (denileukin diftitox) for cutaneous T-cell lymphoma in August 2024. Other late-stage programs include Mino-Lok for catheter-related infections (Phase 3) and a topical treatment for hemorrhoids (Phase 2/3).

Therapeutic areas: OncologyPulmonologyGastroenterologyInfectious Diseases
Modalities: Small moleculeBiologicRecombinant fusion proteinCell therapy
Industry: Investors

Partnerships

Citius PharmaceuticalsHillstream BioPharma

Beyond the preview

Go deeper on Pagoda Resources.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pagoda Resources.

Explore the full profile